News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

AmpliMed Corporation Reports Results from AMP-019; A Randomized Double Blind Trial of Gemcitabine/Placebo vs. Gemcitabine/Amplimexon in Advanced Pancreatic Cancer


7/12/2010 10:44:11 AM

TUCSON, Ariz.--(BUSINESS WIRE)--AmpliMed Corporation, a cancer therapeutics company, today announced results from AMP-019, a randomized double-blind, placebo-controlled Phase II screening trial designed to determine if a Phase III trial was warranted for the combination of gemcitabine (Gemzar, Eli Lilly) plus Amplimexon (AmpliMed Corporation) in patients with advanced pancreatic ductal adenocarcinoma of the pancreas. The statistical design required a 40 percent improvement in overall survival, the primary endpoint, for a positive outcome. Unfortunately, the results showed no improvement in overall survival for the combination of gemcitabine and Amplimexon.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES